Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 8
Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL
Panelists discuss how they evaluate patients for tumor lysis syndrome (TLS) risk, considering factors such as tumor burden, renal function, and prior therapies, and how this assessment influences their decision between prescribing a non-covalent BTK inhibitor or a venetoclax-based regimen for chronic lymphocytic leukemia treatment.
Video content above is prompted by the following:
- How do you assess patients for potential risk of TLS? How does this impact your treatment choice for a non-covalent BTKi over a venetoclax-based regimen?
Related Content:
